Immunovant, Inc.
IMVTReported to SECin USCIK 0001764013Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 22. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Van Tuyl ChristopherChief Legal Officer | Open-market sell | $103,4812,846 shares | Sep 25, 2026 | Van Tuyl ChristopherChief Legal Officer | $103,481 | Open-market sell | 2,846 | Sep 25, 2026 |
| Pande Atul— | Option exercise | nothing paid1,500 shares | Aug 28, 2026 | Pande Atul | nothing paid | Option exercise | 1,500 | Aug 28, 2026 |
| Pande Atul— | Open-market sell | $64,9051,500 shares | Aug 28, 2026 | Pande Atul | $64,905 | Open-market sell | 1,500 | Aug 28, 2026 |
| Pande Atul— | Option exercise | $12,6451,500 shares | Aug 28, 2026 | Pande Atul | $12,645 | Option exercise | 1,500 | Aug 28, 2026 |
| Gloria MelanieChief Operating Officer | Open-market sell | $134,9533,056 shares | Aug 21, 2026 | Gloria MelanieChief Operating Officer | $134,953 | Open-market sell | 3,056 | Aug 21, 2026 |